Minimal Ablative Margin Quantification Using Hepatic Arterial Versus Portal Venous Phase CT for Colorectal Metastases Segmentation: A Dual-center, Retrospective Analysis.

OBJECTIVE

To compare the predictive value of minimal ablative margin (MAM) quantification using tumor segmentation on intraprocedural contrast-enhanced hepatic arterial (HAP) versus portal venous phase (PVP) CT on local outcomes following percutaneous thermal ablation of colorectal liver metastases (CRLM).

METHODS

This dual-center retrospective study included patients undergoing thermal ablation of CRLM with intraprocedural preablation and postablation contrast-enhanced CT imaging between 2009 and 2021. Tumors were segmented in both HAP and PVP CT phases using an artificial intelligence-based auto-segmentation model and reviewed by a trained radiologist. The MAM was quantified using a biomechanical deformable image registration process. The area under the receiver operating characteristic curve (AUROC) was used to compare the prognostic value for predicting local tumor progression (LTP).

RESULTS

Among 81 patients (60 y±13, 53 men), 151 CRLMs were included. During 29.4 months of median follow-up, LTP was noted in 24/151 (15.9%). Median tumor volumes on HAP and PVP CT were 1.7 mL and 1.2 mL, respectively, with respective median MAMs of 2.3 and 4.0 mm (both P< 0.001). The AUROC for 1-year LTP prediction was 0.78 (95% CI: 0.70-0.85) on HAP and 0.84 (95% CI: 0.78-0.91) on PVP (P= 0.002).

CONCLUSIONS

During CT-guided percutaneous thermal ablation, MAM measured based on tumors segmented on PVP images conferred a higher predictive accuracy of ablation outcomes among CRLM patients than those segmented on HAP images, supporting the use of PVP rather than HAP images for segmentation during ablation of CRLMs.